These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8256042)

  • 1. [Need for large sample size in clinical trial and statistical analysis of data from the trials].
    Miyahara H
    Kokyu To Junkan; 1993 Nov; 41(11):1025-32. PubMed ID: 8256042
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
    Shuster JJ; Jones LS; Salmon DA
    Stat Med; 2007 Oct; 26(24):4375-85. PubMed ID: 17768699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies.
    van der Net JB; Janssens AC; Eijkemans MJ; Kastelein JJ; Sijbrands EJ; Steyerberg EW
    Eur J Hum Genet; 2008 Sep; 16(9):1111-6. PubMed ID: 18382476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data.
    Lonn EM; Yusuf S
    Can J Cardiol; 1997 Oct; 13(10):957-65. PubMed ID: 9374952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical methodology of meta-analysis of individual patient data using a survival outcome.
    Katsahian S; Latouche A; Mary JY; Chevret S; Porcher R
    Contemp Clin Trials; 2008 Mar; 29(2):220-30. PubMed ID: 17884735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes.
    Smith CT; Williamson PR; Marson AG
    J Eval Clin Pract; 2005 Oct; 11(5):468-78. PubMed ID: 16164588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.
    Rondeau V; Michiels S; Liquet B; Pignon JP
    Stat Med; 2008 May; 27(11):1894-910. PubMed ID: 18069745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of cumulative incidence function under the proportional hazards model.
    Cheng SC; Fine JP; Wei LJ
    Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tree-augmented Cox proportional hazards models.
    Su X; Tsai CL
    Biostatistics; 2005 Jul; 6(3):486-99. PubMed ID: 15831575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mega-trials vs. meta-analysis: precision vs. heterogeneity?
    Shrier I; Platt RW; Steele RJ
    Contemp Clin Trials; 2007 May; 28(3):324-8. PubMed ID: 17188025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statistical analysis of community-based studies -- presentation and comparison of possible solutions with reference to statistical meta-analytic methods].
    Twardella D; Bruckner T; Blettner M
    Gesundheitswesen; 2005 Jan; 67(1):48-55. PubMed ID: 15672306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
    Sweeting MJ; Sutton AJ; Lambert PC
    Stat Med; 2004 May; 23(9):1351-75. PubMed ID: 15116347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.
    Pogue J; Walter SD; Yusuf S
    Clin Trials; 2009 Jun; 6(3):239-51. PubMed ID: 19528133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial outcome in neuropathic pain: relationship to study characteristics.
    Katz J; Finnerup NB; Dworkin RH
    Neurology; 2008 Jan; 70(4):263-72. PubMed ID: 17914067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease.
    Johnson SM; Karvonen CA; Phelps CL; Nader S; Sanborn BM
    J Womens Health (Larchmt); 2003 Jun; 12(5):449-57. PubMed ID: 12869292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
    Nelson CL; Sun JL; Tsiatis AA; Mark DB
    Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low triiodothyronine and cardiovascular disease.
    Tripepi G; Zoccali C
    Circulation; 2003 Jul; 108(4):e29-30; author reply e29-30. PubMed ID: 12885740
    [No Abstract]   [Full Text] [Related]  

  • 19. Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses.
    Michiels S; Baujat B; Mahé C; Sargent DJ; Pignon JP
    J Clin Epidemiol; 2005 Mar; 58(3):238-45. PubMed ID: 15718112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.